Skip to main content
Signal8

Karyopharm Therapeutics Inc. (KPTI)

Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Karyopharm Therapeutics Inc. logo

Karyopharm Therapeutics Inc.

OTC:KPTIOTC (suspended from Nasdaq on Nov 11, 2026)Sub-class of KPTIQHealthcare
Mkt Cap$395K
EV-
Float21.53M
O/S22.68M
VOL146.51M sh
$ Vol$5.23M
RVOL5.19×
Inst Own76.4%
SI38.2%
Net Cash/Sh-
Dilution
Karyopharm Therapeutics Inc. logoOTC:KPTI

Karyopharm Therapeutics Inc. (KPTI) dilution facts from SEC filings

Snapshot as of Jun 30, 2026, built from 54 SEC filings.

Shelf registration
S-3 filed May 4, 2026, effective May 14, 2026
Source: 10-Q filed Aug 13, 2026
At-the-market (ATM) program
Yes, sales agreement dated Feb 17, 2023
Source: 10-Q filed Aug 13, 2026
Warrants outstanding
7 warrant series recorded as outstanding
Most recent offering
PIPE, closed Mar 26, 2026
Source: 10-Q filed Aug 13, 2026

Check another stock for dilution

Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.

Unlock with Signal8 Pro